Professional Documents
Culture Documents
Glanzmann Thrombasthenia
Glanzmann Thrombasthenia
Etiology and pathogenesis. Revealed two types of disease Glyantsmanna: Type A (9? Or p) and
type B (9S). The development of diseases associated with abnormalities glikoprotei-on IIb / Sha
and decreased activity glitseraldegidfosfat dehydrogenase and pyruvate kinase in platelets, which
leads to lack of blood clot retraction, disruption of the morphology of platelets, reducing the
ability of platelet adhesion, disruption of platelet aggregation, clotting time and platelet count
were normal.
Diagnosis based on clinical and laboratory data. For clot-asthenia Glyantsmanna characterized
by:
Treatment. When treating trombastenii Glyantsmanna use drugs that enhance adhesively-
aggregation properties of platelets: aminokapro-new acid etamzilat; metabolic means [for
example, trifosade-nin (ATP), magnesium preparations]. In addition, appoint calcium chloride,
al-korutin, local hemostatic means.